title: Reversal of renal dysfunction by targeted administration of VEGF into the stenotic kidney: a novel potential therapeutic approach.
abstract: Renal microvascular (MV) damage and loss contribute to the progression of renal injury in renovascular disease (RVD). Whether a targeted intervention in renal microcirculation could reverse renal damage is unknown. We hypothesized that intrarenal vascular endothelial growth factor (VEGF) therapy will reverse renal dysfunction and decrease renal injury in experimental RVD. Unilateral renal artery stenosis (RAS) was induced in 14 pigs, as a surrogate of chronic RVD. Six weeks later, renal blood flow (RBF) and glomerular filtration rate (GFR) were quantified in vivo in the stenotic kidney using multidetector computed tomography (CT). Then, intrarenal rhVEGF-165 or vehicle was randomly administered into the stenotic kidneys (n = 7/group), they were observed for 4 additional wk, in vivo studies were repeated, and then renal MV density was quantified by 3D micro-CT, and expression of angiogenic factors and fibrosis was determined. RBF and GFR, MV density, and renal expression of VEGF and downstream mediators such as p-ERK 1/2, Akt, and eNOS were significantly reduced after 6 and at 10 wk of untreated RAS compared with normal controls. Remarkably, administration of VEGF at 6 wk normalized RBF (from 393.6 ± 50.3 to 607.0 ± 45.33 ml/min, P < 0.05 vs. RAS) and GFR (from 43.4 ± 3.4 to 66.6 ± 10.3 ml/min, P < 0.05 vs. RAS) at 10 wk, accompanied by increased angiogenic signaling, augmented renal MV density, and attenuated renal scarring. This study shows promising therapeutic effects of a targeted renal intervention, using an established clinically relevant large-animal model of chronic RAS. It also implies that disruption of renal MV integrity and function plays a pivotal role in the progression of renal injury in the stenotic kidney. Furthermore, it shows a high level of plasticity of renal microvessels to a single-dose VEGF-targeted intervention after established renal injury, supporting promising renoprotective effects of a novel potential therapeutic intervention to treat chronic RVD.
authors.affiliation: Dept. of Physiology and Biophysics, Dept. of Medicine, Univ. of Mississippi Medical Center, 2500 N. State St., Jackson, MS 39216-4505, USA. achade@umc.edu
authors.forename: Alejandro R
authors.initials: AR
authors.lastname: Chade
authors.forename: Silvia
authors.initials: S
authors.lastname: Kelsen
mesh_terms: D058186:Acute Kidney Injury / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D003404:Creatinine / Q000097:blood; D018374:LLC-PK1 Cells; D018919:Neovascularization, Physiologic / Q000187:drug effects* / Q000502:physiology; D020127:Recovery of Function / Q000187:drug effects / Q000502:physiology; D012078:Renal Artery Obstruction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D012079:Renal Circulation / Q000187:drug effects* / Q000502:physiology; D012083:Renin / Q000097:blood; D034421:Sus scrofa; D013552:Swine; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology*; D055114:X-Ray Microtomography
chemical_list: D042461:Vascular Endothelial Growth Factor A; D003404:Creatinine; D012083:Renin